Precision Oncology for Patients: Why Tumor Tests Don’t Reach Everyone

October 10, 2026

Precision Oncology for Patients: Why Tumor Tests Don’t Reach Everyone

Precision oncology matches cancer treatment to a tumor’s molecular profile rather than only where it started in the body. For patients, that shift can mean a different drug, a therapy once reserved for another cancer type, or entry into a clinical trial built around a specific genetic change. We wrote this guide so you can understand how that matching actually happens, step by step, and where hope still outpaces access.

TL;DR:

• Ask about the assay and its detection limits: targeted panels miss changes beyond their targets, and a negative liquid biopsy does not exclude actionable variants.
• A molecular tumor board can rank findings by evidence, but a variant of uncertain significance has uncertain clinical meaning and should not guide treatment alone.
• An actionable alteration does not guarantee benefit: matched drugs may lack approval or insurance coverage, and trial participants must meet additional eligibility criteria.
• Profiling may confirm that standard chemotherapy or radiation remains the best option, so a result that leaves treatment unchanged can still guide care.
• Ask your treatment center whether it offers molecular tumor board review and typical report turnaround, since specialist access varies by location and institution.

Table of Contents

• What precision oncology covers and how it differs from “personalized medicine”
• How tumor profiling works: from biopsy to clinical report
• Interpreting results: molecular tumor boards and knowledgebases
• Clinical applications: targeted drugs, immunotherapy biomarkers, and tissue-agnostic approvals
• Evidence and outcomes: what the research shows about benefits and limits
• Implementation challenges: cost, infrastructure, and equity
• How HCRF-funded research moves precision oncology forward
• Why we believe clear explanations matter as much as new science
• Join us at HCRF events supporting precision oncology research
• FAQ
• Sources

What precision oncology covers and how it differs from “personalized medicine”

The terms get used interchangeably, but they mean different things, and the difference matters to anyone trying to understand their own diagnosis. “Personalized medicine” suggests a treatment built from scratch for one person. That is not quite what happens, and experts caution that the word can mislead patients into expecting something wholly bespoke. What actually happens is closer to careful matchmaking: clinicians identify which molecular subgroup a tumor belongs to, then choose the treatment already known to work best for that subgroup. That is precision medicine, and the FDA describes it as matching the right drugs or treatments to the right people based on genetic or molecular understanding of disease.

A shared vocabulary helps here, because the jargon can feel like a wall between patients and their own care team.

• Biomarker: a measurable molecular feature, such as a protein level or a gene change, that signals how a cancer will behave or respond to treatment.
• Molecular profiling: laboratory testing that maps a tumor’s genetic and molecular makeup, usually from a tissue or blood sample.
• Actionable variant: a genetic change for which a specific treatment decision exists, whether that is a drug, a trial, or a change in monitoring.
• Targeted therapy: a drug designed to act on a specific molecular abnormality rather than killing all rapidly dividing cells.
• Tissue-agnostic approval: regulatory clearance for a drug based on a biomarker present across multiple cancer types, not on where the tumor originated.

The NIH describes precision oncology as the use of molecular fingerprints to divide cancers into more precise types, guiding treatment by a tumor’s DNA signature rather than its tissue of origin alone. A HER2-positive breast cancer and a HER2-positive stomach cancer, for instance, can both respond to therapies built around that same marker. An ALK gene rearrangement in lung cancer points toward a different class of drug entirely than an ALK-negative tumor of the same type and stage would call for. And tissue-agnostic approvals now let certain biomarker-matched drugs reach patients regardless of where their cancer started, a genuine departure from decades of organ-by-organ drug development.

How tumor profiling works: from biopsy to clinical report

Getting from a patient’s tumor to a treatment recommendation involves a longer chain than most people expect, and each link in that chain affects how reliable the final answer is.

1. Sample collection: a tissue biopsy or a blood draw for liquid biopsy, which captures circulating tumor DNA shed into the bloodstream.
2. Laboratory assay: the sample goes through next-generation sequencing (NGS), which can mean a targeted panel of dozens to hundreds of genes, whole-exome or whole-genome sequencing, RNA testing to catch fusion events, or proteomic analysis of protein expression.
3. Bioinformatics pipeline: raw sequencing data is processed, aligned to reference genomes, and filtered to separate true tumor variants from background noise.
4. Clinical report: a pathologist or molecular geneticist translates the variant list into a document the treating oncologist can act on.

Each test type trades off differently. Targeted NGS panels are faster and cheaper but only look where they are told to look. Whole-exome or whole-genome sequencing casts a wider net and can surface unexpected findings, at higher cost and with longer turnaround. RNA testing picks up gene fusions that DNA sequencing can miss. Liquid biopsy spares patients a repeat invasive procedure and works well for serial monitoring, though its sensitivity varies by tumor type and disease burden, meaning a negative result does not always rule out an actionable change.

Quality matters as much as test choice. Tumor fraction, the proportion of tumor DNA present in a sample relative to normal tissue, affects whether a real variant gets detected at all. Low tumor fraction can produce a falsely reassuring negative report. Turnaround time matters clinically too: a patient waiting on treatment decisions cannot wait indefinitely for results. Lab accreditation offers some assurance that these variables are controlled, which is part of why clinicians increasingly ask which assay was used and how it performed, not just what it found.

Pro Tip: If a report comes back negative for an expected alteration, ask whether a paired normal sample was tested and what the assay’s limit of detection was before assuming the biomarker is truly absent.

Paired normal testing, comparing tumor DNA against a patient’s non-cancerous tissue, helps distinguish somatic changes (present only in the tumor) from germline changes (inherited and present in every cell), a distinction the National Cancer Institute addresses directly. Precision oncology treatment decisions rest primarily on somatic findings, while germline results can carry implications for family members and future cancer risk.

For patients whose profiling involves imaging alongside molecular testing, integrated reads matter too. Remote subspecialty imaging review, such as the PET-CT interpretation services offered by teleradiology partners, can help close gaps where local imaging expertise is limited, supporting the same goal of a complete, accurate picture before treatment decisions get made.

Interpreting results: molecular tumor boards and knowledgebases

A list of genetic variants is not, by itself, a treatment plan. That gap is where the molecular tumor board (MTB) comes in. An MTB brings together an oncologist, a pathologist, a molecular geneticist, and a bioinformatician to review a patient’s sequencing report and decide what it actually means for care. This kind of structured, multidisciplinary review is increasingly considered essential, because interpreting genomic reports correctly requires expertise that no single specialty holds alone.

To do that work consistently, MTBs lean on curated knowledgebases, resources like CIViC, JAX CKB, and the Cancer Genome Interpreter, which catalog known variants alongside the strength of evidence linking them to specific treatments. A review of these knowledgebases found they assign evidence levels, distinguishing a variant with strong clinical trial support from one with only preliminary laboratory data behind it. That distinction shapes everything downstream.

Variants generally sort into a few categories:

• Approved therapy: a drug is already cleared for use based on this exact biomarker.
• Off-label or compassionate use: evidence supports the match, but the drug is not formally approved for this cancer type.
• Clinical trial match: a trial exists specifically for patients with this alteration.
• Variant of uncertain significance (VUS): the change is real, but its clinical meaning is not yet established.

Communicating that last category honestly, without overstating what a VUS means or underselling a genuine trial match, is part of what separates careful oncology practice from false reassurance.

Clinical applications: targeted drugs, immunotherapy biomarkers, and tissue-agnostic approvals

This is where molecular profiling meets the exam room. Targeted therapies built around specific biomarkers, HER2 amplification, ALK rearrangements, BRAF mutations, have already reshaped how several cancers are treated, with biomarker-positive patients seeing meaningful benefit from drugs chosen specifically for that alteration rather than a one-size-fits-all chemotherapy regimen.

Immunotherapy adds another layer of biomarker-driven decision-making:

• PD-L1 expression: helps predict which patients are more likely to respond to checkpoint inhibitor therapy.
• MSI-H/dMMR status: identifies tumors with mismatch repair deficiency, often highly responsive to immunotherapy regardless of where the cancer started.
• TMB (tumor mutational burden): a measure of how many mutations a tumor carries, used alongside other markers to inform immunotherapy decisions.

Tissue-agnostic approvals represent one of the clearest signs of how far this field has moved. Rather than approving a drug for “lung cancer” or “colon cancer,” regulators now clear certain biomarker-matched therapies for use across any solid tumor type that carries the relevant marker. The NIH highlights molecular fingerprinting as the basis for this kind of cross-tumor treatment logic, a genuine break from the organ-based drug development model that dominated oncology for decades.

A biomarker match often does more than guide an existing prescription: it can open the door to a clinical trial. Trials increasingly enroll patients by molecular alteration rather than cancer type, through adaptive designs and master protocols that the WHO identifies as valuable tools for generating evidence in small, biomarker-defined patient groups. For patients facing cancers with limited standard options, a trial match found through profiling can be the most meaningful outcome of the entire testing process. Readers interested in how this plays out for a specific disease can see our pancreatic cancer clinical trials and immunotherapy guide for a closer look at trial access in practice.

Evidence and outcomes: what the research shows about benefits and limits

The honest picture includes both real gains and real limits, and patients deserve both halves. Comprehensive genomic profiling identifies an actionable alteration in numerous cases of advanced solid tumors in some real-world series (https://pmc.ncbi.nlm.nih.gov/articles/PMC6143048/), a figure that reflects how far sequencing technology has come. But finding an actionable alteration is not the same as that finding changing a patient’s outcome.

Several factors sit between “actionable” and “beneficial.” Drug access matters: a matched therapy might exist but not be approved, covered, or available where a patient is being treated. Trial eligibility matters: a patient may carry the right mutation but not meet other criteria for the trial built around it. Tumor biology itself matters, since a single alteration rarely tells the whole story of how a cancer will behave.

It is also worth saying plainly that profiling sometimes confirms, rather than changes, the plan already in motion. The National Cancer Institute notes that precision oncology testing can affirm that standard chemotherapy or radiation remains the most appropriate choice, which is itself a useful and clarifying result, not a failed test. Understanding this distinction helps set realistic expectations before testing begins, rather than after.

Implementation challenges: cost, infrastructure, and equity

None of this works at scale without solving some genuinely hard problems, and we think patients and donors alike deserve a clear-eyed look at them.

• Cost and reimbursement: comprehensive NGS panels and companion diagnostics carry real costs, and coverage varies by insurer, region, and test type.
• Infrastructure gaps: accredited labs, functioning MTBs, and bioinformatics capacity are unevenly distributed, concentrated at larger academic centers.
• Workforce training: interpreting genomic reports takes specialized expertise that remains in short supply relative to demand.
• Data governance: informed consent, patient privacy, and secondary use of genomic data raise questions that policy is still catching up to.

The WHO’s policy review names high diagnostic costs, limited NGS infrastructure, and workforce shortages as central barriers to broader adoption, alongside the governance questions that come with handling genetic data responsibly. Geography compounds all of this: patients far from major cancer centers often face longer waits, fewer trial options, and less access to the specialists who sit on an MTB.

Pro Tip: If you or a loved one is weighing genomic testing, ask the treating center directly about MTB access and typical report turnaround time, since both vary widely between community and academic settings.

These are not reasons to doubt the science. They are the reasons research funding matters as much as research itself.

How HCRF-funded research moves precision oncology forward

We fund innovative, high-risk research that traditional grant cycles often pass over, focused on work being carried out at a nationally recognized cancer center. We support projects probing the tumor microenvironment and adaptive trial designs, both of which feed directly into how profiling results become real treatment options rather than interesting data points. Our coverage of tumor microenvironment research and adaptive clinical trial design shows how that funding translates into clinical practice, and our patient navigator resources help connect patients to trial access when a biomarker match points toward one.

Why we believe clear explanations matter as much as new science

We have watched families sit across from an oncologist, hearing words like “actionable variant” for the first time while already carrying so much fear. Explaining precision oncology clearly is not a side project for us. It is part of the mission, because hope grows faster when people understand what they are being offered. Every donor who funds our research is also funding the infrastructure, the molecular tumor boards, the trial access, that turns a genetic report into a real chance. Learn more about the work we support at HCRF.

— HCRF

Join us at HCRF events supporting precision oncology research

We invite you to stand with us at two events built around this exact mission. Cocktails for a Cure kicks off our fundraising season with an evening of connection in service of research that traditional funding often overlooks, and you can find details on the Cocktails for a Cure event page. Our flagship evening, HCRF’s 13th Annual Wings To Cure Gala, brings our community together for a night of hope and homecoming, with full details on the Wings To Cure Gala page.

Every dollar raised helps fund the labs, the molecular tumor boards, and the trial infrastructure that turn a tumor’s molecular profile into a real treatment path. We would love for you to join us. Reserve your seat today through either event page above and help carry this light of hope forward.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

Is precision oncology a legitimate, evidence-based approach?

Yes. Regulatory bodies including the FDA and the NIH describe precision oncology as an established approach that uses molecular and genetic understanding of a tumor to guide treatment selection. It is actively used in cancer centers and incorporated into regulatory drug approvals, including tissue-agnostic clearances.

What are the four P’s commonly linked to precision medicine?

Definitions vary across sources, but a commonly cited version describes medicine moving toward being predictive, preventive, personalized, and participatory. In the oncology context, this generally reflects the shift toward anticipating risk, tailoring treatment to molecular profiles, and involving patients more actively in decisions.

What are the main downsides or limits of precision medicine in cancer care?

Key limits include cost and uneven insurance coverage, infrastructure gaps outside major academic centers, and workforce shortages in genomic interpretation, as outlined in WHO policy analysis. An actionable genetic finding also does not always translate into a treatment that is available, approved, or effective for that specific patient.

What typically drives most cancer cases?

Cancer generally arises from an accumulation of genetic changes, both inherited and acquired over a lifetime, rather than a single universal cause. The National Cancer Institute’s overview of genetic mutations distinguishes inherited germline changes from the somatic mutations that accumulate in tumor cells and are the primary focus of precision oncology testing.

Sources

These sources back the clinical claims throughout this guide and offer deeper reading for patients and clinicians alike: government guidance from the FDA and NIH, WHO policy analysis on implementation barriers, and peer-reviewed research on genomic profiling and knowledgebases.

• FDA: Understanding Precision Medicine (overview)
• NIH: Precision oncology
• WHO: Precision oncology and implementation considerations

Recommended

• Cancer Clinical Trial Eligibility: What Qualifies You to Enroll
• The Tumor Microenvironment: What Researchers and Clinicians Need to Know
• Clinician Playbook to Secure Expanded Access for U.S. Cancer Patients
• Clinician Update: Degraders, KRAS, AI Drive 2026 Targeted Therapy